Individualized Gene Therapy: US FDA Considering Device-Like Manufacturing Approval Process

 
• By Derrick Gingery

CBER Director Peter Marks said the agency could streamline development by allowing sponsors to depend on an already-approved manufacturing platform and reviewing any modifications that are proposed.

Genetic engineering and gene manipulation concept. Hand is replacing part of a DNA molecule. 3D rendered illustration of DNA.
The FDA is expecting to receive many more applications for individualized treatments, both in its small-molecule drug and gene therapy divisions. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies